yellow_bluff: Unfortunately AZN is good at what they do. ie Crestor.
They have considerably more dedicated Reps, and pre-existing relationships in the Cardiology Community. There are large Metropolitan areas that have no Rep coverage at all . Southern California for example. I have personally called quite a few Cardiologists in LA, Beverly Hills, and San Diego ( a major biotech
hub) and not one MD I called had seen a Amarin Rep. GIA is suicide
despite many on this board who feel Reps are not the way to market a new drug. GSK, MRK, PFE and AZN are getting their drugs written for.
Though our prescriptions are moving upward week over week, I can't
envision a successful scenario for AMRN without having a deep pockets large Pharma partner to market the hell out of Vascepa. My
major worry is that despite our waving Pom Poms on this site, just maybe no BP wants to get involved with us. I'd love to hear some balanced comments on this real fear. Why else is the short interest
continuing to rise. What are we missing ????